GPR26 Activators
GPR26 Activators are specialized compounds that indirectly increase the functional activity of GPR26 through a variety of signaling pathways, leading to amplified signaling events. Forskolin acts by directly stimulating adenylyl cyclase, which results in a rise in cAMP; this cascade, following the activation of protein kinase A (PKA), may lead to the phosphorylation of components involved in GPR26 signaling, thereby enhancing its activity. Isoproterenol, through its agonistic action on beta-adrenergic receptors, similarly increases cAMP and indirectly supports GPR26 activity via shared downstream effects on PKA, which is known to phosphorylate proteins that can modulate GPR26's functional state. L-Arginine, serving as a nitric oxide precursor, and Sildenafil, as a PDE5 inhibitor, both increase the levels of cGMP, which is a pivotal messenger in cellular signaling and could, by affecting cyclic nucleotide-regulated ion channels, bolster GPR26's activity.
Furthermore, adenosine, by interacting with its receptors, elevates cAMP, indirectly fostering GPR26's role through enhanced PKA activity which may affect GPR26's signaling pathway. Zaprinast and Rolipram, by inhibiting PDEs, lead to higher cGMP and cAMP levels respectively, which can potentiate GPR26's activity by altering the signaling landscape that GPR26 is part of. Carbachol and Nicotine, via cholinergic receptor activation, modify intracellular calcium signaling, a crucial secondary messenger in numerous pathways that could intersect with GPR26's regulatory mechanisms. IBMX, a broad PDE inhibitor, increases both cAMP and cGMP levels, potentially affecting cyclic nucleotide-regulated signaling pathways and thereby indirectly influencing GPR26 function. Lastly, Yohimbine, by antagonizing alpha-2 adrenergic receptors, and Vardenafil, another PDE5 inhibitor, elevate norepinephrine and cGMP levels respectively, which can lead to an indirect enhancement of GPR26 signaling through the modulation of intracellular secondary messenger systems and associated kinase activities.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin directly stimulates adenylyl cyclase, increasing intracellular cAMP levels. The elevation of cAMP can lead to the activation of protein kinase A (PKA), which may phosphorylate GPR26 or associated regulatory proteins, thereby enhancing GPR26 signaling. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol, a non-selective beta-adrenergic agonist, leads to the activation of adenylyl cyclase via G protein-coupled receptor signaling. This activation results in increased cAMP and subsequent PKA activation, which could phosphorylate and enhance GPR26 activity indirectly due to the shared signaling cascade. | ||||||
L-Arginine | 74-79-3 | sc-391657B sc-391657 sc-391657A sc-391657C sc-391657D | 5 g 25 g 100 g 500 g 1 kg | $20.00 $31.00 $61.00 $219.00 $352.00 | 2 | |
L-Arginine is a precursor for the synthesis of nitric oxide (NO), a diffusible second messenger that activates guanylyl cyclase, thereby increasing cGMP levels in cells. Elevated cGMP may modulate GPR26 activity indirectly by influencing the signaling pathways that GPR26 is part of, such as those involving cyclic nucleotide-regulated ion channels. | ||||||
Adenosine | 58-61-7 | sc-291838 sc-291838A sc-291838B sc-291838C sc-291838D sc-291838E sc-291838F | 1 g 5 g 100 g 250 g 1 kg 5 kg 10 kg | $34.00 $48.00 $300.00 $572.00 $1040.00 $2601.00 $4682.00 | 1 | |
Adenosine interacts with adenosine receptors, which are G protein-coupled receptors that can increase intracellular cAMP levels upon activation. The increase in cAMP can lead to enhanced PKA activity, which may subsequently influence GPR26 signaling through phosphorylation of proteins within the GPR26 signaling pathway. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast inhibits PDEs, which leads to an increase in cGMP levels. Elevated levels of cGMP can indirectly enhance GPR26 signaling by altering the balance of signaling molecules and influencing pathways that GPR26 participates in, such as those that regulate ion channel activity. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective inhibitor of PDE4, which specifically hydrolyzes cAMP. Inhibition of PDE4 by Rolipram leads to increased cAMP levels, potentially enhancing GPR26 activity by increasing PKA signaling, which could indirectly affect the phosphorylation state of GPR26 or proteins within its signaling pathway. | ||||||
Carbachol | 51-83-2 | sc-202092 sc-202092A sc-202092C sc-202092D sc-202092B sc-202092E | 1 g 10 g 25 g 50 g 100 g 250 g | $122.00 $281.00 $388.00 $683.00 $1428.00 $3060.00 | 12 | |
Carbachol is a cholinergic agonist that activates acetylcholine receptors, which can lead to the modulation of intracellular calcium levels. Changes in calcium signaling could influence GPR26 function indirectly as calcium is a secondary messenger that interacts with various signaling pathways, some of which may intersect with GPR26 regulatory mechanisms. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of PDEs, leading to increased levels of both cAMP and cGMP by preventing their degradation. Higher concentrations of these cyclic nucleotides can enhance GPR26 signaling indirectly by affecting the signaling pathways that involve cyclic nucleotide-regulated proteins, possibly altering GPR26 activity. | ||||||
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $51.00 $171.00 $530.00 | 2 | |
Yohimbine is an alpha-2 adrenergic receptor antagonist that can lead to increased release of norepinephrine, which in turn can increase cAMP levels via beta-adrenergic receptor stimulation. This increase in cAMP may indirectly enhance GPR26 signaling through PKA activation and subsequent phosphorylation of proteins in the GPR26 signaling pathway. | ||||||
Vardenafil | 224785-90-4 | sc-362054 sc-362054A sc-362054B | 100 mg 1 g 50 g | $526.00 $735.00 $16653.00 | 7 | |
Vardenafil, a PDE5 inhibitor similar to Sildenafil, prolongs the action of cGMP by preventing its breakdown. The ensuing accumulation of cGMP can indirectly influence GPR26 signaling pathways by modulating the activity of cyclic nucleotide-regulated ion channels | ||||||